The Effects of Adverse Events and Associated Costs on Value-Based Care for Metastatic Pancreatic Ductal Adenocarcinoma
**Background:** Rising oncology healthcare costs have led to value-based care reimbursement models that coordinate care and improve quality while reducing overall spending. These models are increasingly important for traditional Medicare and other payers. **Objectives:** To compare the incidence of...
Saved in:
Main Authors: | Prachi Bhatt, Jared Hirsch, Paul Cockrum, George Kim, Gabriela Dieguez |
---|---|
Format: | Article |
Language: | English |
Published: |
Columbia Data Analytics, LLC
2024-12-01
|
Series: | Journal of Health Economics and Outcomes Research |
Online Access: | https://doi.org/10.36469/001c.124367 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Complete Radiologic Response of Metastatic Pancreatic Ductal Adenocarcinoma to Microwave Ablation Combined with Second-Line Palliative Chemotherapy
by: Hakon Blomstrand, et al.
Published: (2020-01-01) -
Modulation of myeloid and T cells in vivo by Bruton’s tyrosine kinase inhibitor ibrutinib in patients with metastatic pancreatic ductal adenocarcinoma
by: Li Zhang, et al.
Published: (2023-01-01) -
Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma
by: Caroline Y. K. Fong, et al.
Published: (2019-01-01) -
Targeted therapy for pancreatic ductal adenocarcinoma: Mechanisms and clinical study
by: Heng‐Chung Kung, et al.
Published: (2023-04-01) -
Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)